Lataa...
Improvement of renal function by changing the bone-modifying agent from zoledronic acid to denosumab
BACKGROUND: In order to help in selecting the optimum bone-modifying agent (BMA; zoledronic acid or denosumab), we investigated the impact of the BMA on the renal function of patients with bone metastases. MATERIALS AND METHODS: The present study consisted of 118 patients who were treated with denos...
Tallennettuna:
| Julkaisussa: | Int J Clin Oncol |
|---|---|
| Päätekijät: | , , , , , , , |
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
Springer Japan
2016
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5124438/ https://ncbi.nlm.nih.gov/pubmed/27402103 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10147-016-1019-4 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|